Osimertinib-Associated Benign Ocular Hyperpigmentation: A Case Report.
Nuhansi Wijesinghe, Jennifer Chin, Ann Chung et al.
✦ AI-curated · Sources linked
Case in brief
An Asian woman in her sixth decade with an 8-year history of non-small-cell lung cancer was found incidentally to have bilateral benign hyperpigmentation of the conjunctiva and corneal epithelium. The pigmentation involved the caruncles and extended to the lid margins in both eyes. She had received osimertinib for 4 years. The report associated the ocular pigmentation with long-term osimertinib use; no treatment or subsequent resolution was described.
What made this case unusual
The pigmentation affected both conjunctiva and corneal epithelium, with involvement extending from the caruncles to the lid margins.
Diagnostic / clinical pearl
In a patient taking osimertinib, benign ocular hyperpigmentation should be distinguished from primary acquired melanosis, which can progress to conjunctival melanoma.